Alligator Bioscience focuses on ATOR-1017 and mitazalimab
Lund, Sweden, October 22, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the decision to focus its resources on the t ...
Alligator Bioscience appoints Gayle Mills as Chief Business Officer
Lund, Sweden, September 28, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today the appointment of Gayle Mills as Chief Bu ...
Alligator Bioscience launches a new immuno-oncology concept
Lund, Sweden, September 24, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company launches a new concept fo ...
Alligator Bioscience receives patent approval for the drug candidate ATOR-1015
Lund, Sweden, September 16, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the United States Patent and Trademar ...
Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015
Lund, Sweden, September 9, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today updated timelines indicating 3-6 months del ...
Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study
Lund, Sweden, September 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today biomarker data from a recently performed cl ...
Alligator Bioscience: Encouraging interim safety data in ATOR-1017 clinical Phase I study
Lund, Sweden, August 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today interim safety data from its ongoing clinical ...
Alligator Bioscience Virtual R&D Day – August 27, 2020
Lund, Sweden, August 25, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) invites to a virtual R&D Day on August 27 at 2:00 p.m. – ...
Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day August 27, 2020
Lund, Sweden, August 25, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) will give status updates and details on the recent clinical d ...